Month: May 2016

2016: KEI objections to NIH licenses to Vital Spark, Kalytera Therapeutics, CB1 receptor mediating compounds

Posted on by KEI Staff

Warning: call_user_func_array() expects parameter 1 to be a valid callback, function 'wp_embed_excerpt_more' not found or invalid function name in /home/keionli38/public_html/wp-includes/class-wp-hook.php on line 341

(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) May 4, 2016 Betty Tong, Ph.D. Senior Licensing and Patenting Manager Technology Advancement Office National Institute of Diabetes and Digestive and Kidney Diseases 12A South…

2016: NIH FOIA office withholds all records related to exclusive license on HER2+ breast cancer treatment technology

Posted on by Zack Struver

Other KEI comments on NIH licenses are found here: /nih-licenses

In response to a February request under the Freedom of Information Act (FOIA) for documents related to the grant of an exclusive patent license on a HER2+ breast cancer treatment technology, the National Institutes of Health (NIH) withheld in full all responsive records.

Continue Reading →

Uncategorized

WHO CEWG 2016: Statement of Health Action International, Knowledge Ecology International and STOPAIDS

Posted on by Thiru

On Monday, 2 May 2016, the World Health Organization (WHO) convened the 2016 open-ended member states meeting of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG). The 2016 CEWG is chaired by Bhanu Pratap Sharma, Secretary, Ministry of Health and Family Welfare, Government of India. The Vice-Chair is Tania Dussey- Cavassini, Vice-Director General, Ambassador for Global Health, Federal Office of Public Health, Switzerland.

Continue Reading →

Uncategorized